室管膜瘤的临床治疗及分子病理学进展  

Progress on clinical therapeutic strategies and molecular pathogenesis of ependymoma

作　　者：陈峻叡 丁建波 秦智勇[1] 

机构地区：[1]复旦大学附属华山医院神经外科,上海200040 [2]上海伽马刀医院,上海200235

出　　处：《转化医学电子杂志》2017年第7期33-36,共4页E-Journal of Translational Medicine

基　　金：基金项目:卫生部医药科技中心(W2012F2003)

摘　　要：室管膜瘤是一种少见的中枢神经系统上皮性肿瘤,起源于脑室系统及脊髓中央管的室管膜细胞,其发生率大约占颅内原发肿瘤的2.1%.随着2015年美国NCCN肿瘤临床治疗指南的更新,室管膜瘤的临床规范化治疗已有基本共识.然而,由于室管膜瘤本身发生部位的多样性及肿瘤的异质性,患者的预后存在较大的个体差异.近几年临床分子生物学的进展对室管膜瘤的组织学及基因分型等皆有新的认识,在2016年中枢神经系统肿瘤中,首次将基因亚型编列入室管膜瘤病理分型中.本文介绍了室管膜瘤临床特征和治疗方案及近年国际上室管膜瘤的分子生物学进展.Ependymoma, accounting for 2. 1% of the central nervous system tumors, deriving from ependymal cells lining of the cerebral ventricular system and central canal of the spinal cord, is a rare type of malignancy. The 2015 NCCN therapeutic guideline has established the standard with one accord. However, the prognoses of patients are different because of the diversity of ependymoma location and tumor heterogeneity. Latest molecular and genetic researches have created a new landscape of tumor histology and pathogenesis, and it＇s the first time that genetic subtype ependymoma has been collected into the WHO classification of central nervous system tumor. Here we reviewed the clinical characteristics and progress on molecular biology of ependymoma recently.

关 键 词：室管膜瘤 分子病理 预后 

分 类 号：R739.41[医药卫生—肿瘤]